Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HIV-1 Rev–binding protein accelerates cellular uptake of iron to drive Notch-induced T cell leukemogenesis in mice
Shariq S. Khwaja, Hudan Liu, Caili Tong, Fang Jin, Warren S. Pear, Jan van Deursen, Richard J. Bram
Shariq S. Khwaja, Hudan Liu, Caili Tong, Fang Jin, Warren S. Pear, Jan van Deursen, Richard J. Bram
View: Text | PDF
Research Article Hematology

HIV-1 Rev–binding protein accelerates cellular uptake of iron to drive Notch-induced T cell leukemogenesis in mice

  • Text
  • PDF
Abstract

Somatic activating mutations in Notch1 contribute to the pathogenesis of T cell acute lymphoblastic lymphoma (T-ALL), but how activated Notch1 signaling exerts this oncogenic effect is not completely understood. Here we identify HIV-1 Rev–binding protein (Hrb), a component of the clathrin-mediated endocytosis machinery, as a critical mediator of Notch-induced T-ALL development in mice. Hrb was found to be a direct transcriptional target of Notch1, and Hrb loss reduced the incidence or delayed the onset of T-ALL in mouse models in which activated Notch1 signaling either contributes to or drives leukemogenesis. Consistent with this observation, Hrb supported survival and proliferation of hematopoietic and T cell precursor cells in vitro. We demonstrated that Hrb accelerated the uptake of transferrin, which was required for upregulation of the T cell protooncogene p21. Indeed, iron-deficient mice developed Notch1-induced T-ALL substantially more slowly than control mice, further supporting a critical role for iron uptake during leukemogenesis. Taken together, these results reveal that Hrb is a critical Notch target gene that mediates lymphoblast transformation and disease progression via its ability to satisfy the enhanced demands of transformed lymphoblasts for iron. Further, our data suggest that Hrb may be targeted to improve current treatment or design novel therapies for human T-ALL patients.

Authors

Shariq S. Khwaja, Hudan Liu, Caili Tong, Fang Jin, Warren S. Pear, Jan van Deursen, Richard J. Bram

×

Figure 2

Hrb is a direct Notch1-regulated transcriptional target.

Options: View larger image (or click on image) Download as PowerPoint
Hrb is a direct Notch1-regulated transcriptional target.
(A) A murine No...
(A) A murine Notch-dependent cell line, T6E12, was utilized for Hrb mRNA and protein analysis. T6E12 cells were transduced with MigR1 (empty vector), MigR1-ICN1, or MigR1-DNMAML1 for 48 hours followed by 24 hours DMSO or GSI (1 μM) treatment as labeled. Hrb mRNA and protein levels were determined by quantitative RT-PCR and Western blot analysis, respectively. Results were obtained from 3 independent experiments. (B) T6E12 cells were treated with GSI (1 μM) for 48 hours to permit accumulation of the gamma-secretase substrate (transmembrane-Notch1 [NTM]). Cells were then washed and replenished with medium containing GSI (mock washout) or medium lacking GSI (washout) in the absence or presence of 20 μM cycloheximide (CHX). Hrb mRNA levels were evaluated by quantitative RT-PCR after 4 hours of additional incubation. Similar results were obtained in 3 independent experiments. (C) ChIP was performed on cross-linked fragmented DNAs prepared from T6E12 cells treated with DMSO or 1 μM GSI for 24 hours. Eluted DNAs were then analyzed by quantitative RT-PCR using primers flanking putative CSL-binding sites (A and B). Amplification of hes1 CSL-binding site served as a positive control to validate ChIP efficiency. The amount of DNA amplified from immunoprecipitated DNAs was normalized to that amplified from input DNA. (D) Western blot of lysates prepared from empty vector– (MigR1) and ICN1-transduced Hrb+/+ and Hrb–/– T cell precursors blotted for Hrb (clone H-300) and actin (loading control). Asterisk indicates nonspecific band. Data are shown as mean ± SD.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts